VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -65.84% | 140.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -65.84% | 140.48% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -65.84% | 140.48% | |||
| SG&A Expenses | -16.64% | 3.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.02% | -26.88% | |||
| Operating Income | 17.99% | 27.98% | |||
| Income Before Tax | 33.20% | 28.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.20% | 28.39% | |||
| Earnings from Discontinued Operations | 0.00% | 0.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.17% | 28.37% | |||
| EBIT | 17.99% | 27.98% | |||
| EBITDA | 18.01% | 28.02% | |||
| EPS Basic | 33.30% | 28.49% | |||
| Normalized Basic EPS | 18.25% | 28.49% | |||
| EPS Diluted | 33.30% | 28.49% | |||
| Normalized Diluted EPS | 18.25% | 28.49% | |||
| Average Basic Shares Outstanding | 0.20% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||